- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01659164
Psychological Treatment for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Psychological Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) - Pilot Evaluation of a New Treatment Manual Based on CBT and DBT
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately one-third of children with ADHD continue to be fully symptomatic into adulthood and many of the remainders often retain some residual problems that require treatment. Thus ADHD is a prevalent and chronic disabling disorder. Drugs provide first line treatment for adults with ADHD but are not enough for everybody, while we still lack proper evidence for promising psychological treatment. In addition to core symptoms of ADHD including regulatory difficulties of attention, activity level and impulses, difficulties with emotional regulation are common.
Follow-up studies of adults with ADHD have shown that only a few patients were offered sufficient treatment and support after the neuropsychiatric assessment and testing. The majority of adults diagnosed with ADHD are offered pharmacological treatment (stimulant medication) as the sole treatment. However, stimulant medication is not effective for up to 20-50 percent of adults as they may not experience symptom reduction or they are unable to tolerate the medication.
Consequently, the possible benefits of identifying and treating individuals with ADHD are extensive. Treatment of ADHD is preferably multimodal, i.e. consisting of more than one intervention.
There has been limited research to date concerning psychosocial treatments for adult ADHD. Studies of cognitive behavioral therapy (CBT) and dialectical behavior therapy (DBT) show that structured short-term therapies are promising in reducing ADHD related symptoms and increasing life quality. Focus in the CBT treatment is to build skills, increasing and compensating for deficits in the executive functioning due to impairments of the frontal lobe. DBT combines change-oriented skills from CBT with acceptance-oriented skills and core mindfulness skills. DBT skills have been tried out and validated as a promising intervention package for adults with ADHD through the research of Steven Safren and Bernd Hesslinger.
The objective of the planned study is to evaluate a new manual for group treatment, with a combination of treatment methods from Safrens and Hesslingers evidence-based treatment manuals. The aim of the pilot project is to create a clinically effective combination of the different methods of treatment, with a high degree of understanding, acceptance, use and perceived usefulness of the patients undergoing treatment. Both qualitative and quantitative data about patients' perceptions and use of the different methods will be collected during and after treatment to increase knowledge of how treatments can be developed and combined in order to better match the needs of patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden
- Internetpsykiatrienheten, Psykiatri Sydväst, SLSO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- * Clinical diagnosis of AD/HD
- * Age 18-65
- 17 or more on the Adult ADHD Self Report Scale (ASRS v1.1)
- Not medically treated for adhd symptoms, or medically treated with central stimulants or comparable substance since at least one month with no significant changes in dosage and where no change in medical treatment is anticipated during the study time frame for the participant.
- No change in any other medical treatment is anticipated during the study time frame for the participant.
- Participant are by investigators considered able to follow through the training protocol and take part in measures taken during the study time frame
The participant hasn´t used drugs the last 3 months.
Exclusion Criteria:
- Diagnosed substance abuse according to DSM-IV criteria within 3 months prior to screening. Earlier episodic substance abuse is not excluding
- Co-existing psychiatric condition that investigators believe will unable the participant to follow through the training protocol and take part in measures taken during the study time frame.
- IQ ≤70 according to a neuropsychological assessment
- * Suicidality risk which is assessed during the first assessment interview.
- Organic brain syndrome
- Serious somatic condition which will unable the participant to participate (through the training protocol)or, is anticipated to have a negative impact on the treatment results
- Autism spectrum disorder (severe)
- Severe depression
- Other current psychological treatment for AD/HD
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group treatment (uncontrolled)
Psychological treatment in group for adults with ADHD (pilot) during 14 weeks with focus on decreasing disabilities due to the condition.
|
14 weeks of group treatment for adults with ADHD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change (from baseline) in ASRS- v 1.1
Time Frame: 14 weeks (post)
|
ADHD Self Report Scale (self rating)
|
14 weeks (post)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change (from baseline) in ADHD Rating Scale
Time Frame: 14 weeks (post)
|
ADHD Rating Scale - assessed by a clinician
|
14 weeks (post)
|
|
Change (from baseline) in EQ-5D
Time Frame: 14 weeks (post)
|
Euroqol - (self report) to measure general health and quality of life
|
14 weeks (post)
|
|
Change (from baseline) in ISI
Time Frame: 14 weeks (post)
|
Insomnia Severity Index - (self report) to measure insomnia symptoms
|
14 weeks (post)
|
|
Change (from baseline) in PSS-4
Time Frame: 14 weeks (post)
|
Perceived Stress Scale - (self report) to measure level of stress in everyday life
|
14 weeks (post)
|
|
Change (from baseline) in Sheehan Disability Scale
Time Frame: 14 weeks (post)
|
Sheehan Disability Scale - (self report) to measure level of disability in everyday life
|
14 weeks (post)
|
|
Change (from baseline) in MADRS-S
Time Frame: 14 weeks (post)
|
Montgomery-Åsberg Depression Rating Scale - (self report) to measure level of depression
|
14 weeks (post)
|
|
Change (from baseline) in DERS
Time Frame: 14 weeks (post)
|
Difficulties of Emotion Regulation Scale - (self report)
|
14 weeks (post)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment evaluation
Time Frame: 14 weeks (post)
|
The investigators design own questions in order to evaluate how the participants have experienced the intervention regarding to knowledge, usage of the treatment methods and possible difficulties that they have experienced during treatment.
Our aim is to use these evaluations to evolve and improve the quality of the treatment manual.
|
14 weeks (post)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Viktor Kaldo, Ph.D., Karolinska Institutet
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012/333-31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
St. Antonius HospitalNot yet recruitingADHD | Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD, Predominantly Hyperactive - Impulsive | Attention Deficit Disorder (ADD) | Hyperactivity | Inattention | ADHD Predominantly Hyperactivity Type | ADHD-not Other Specified | Hyperactivity... and other conditions
-
Wuhan Sports UniversityTerminatedADHD | ADHD - Combined Type | ADHD - Inattentive Type | ADHD - Attention Deficit Disorder With Hyperactivity | ADHD Specifically With Executive Function ImpairmentChina
-
The Hong Kong Polytechnic UniversityRecruiting
-
Loewenstein HospitalWingate InstituteRecruiting
-
Region Örebro CountyActive, not recruiting
-
University of TorontoCompleted
-
Massachusetts General HospitalCenter for Survey Research, University of Massachusetts, BostonCompleted
-
Akili Interactive Labs, Inc.Active, not recruiting
-
L'hôpital Nord-Ouest - Villefranche Villefranche...Completed
-
Johns Hopkins UniversityWithdrawn
Clinical Trials on Group treatment for adults with ADHD
-
Karolinska InstitutetRegion StockholmCompleted
-
Karolinska InstitutetRecruitingAttention Deficit Disorder With or Without Hyperactivity (ADHD)Sweden
-
CogCubed, CorpCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Universitaire Ziekenhuizen KU LeuvenKU Leuven; Research Foundation FlandersCompleted
-
Oslo University HospitalLovisenberg Diakonale HospitalUnknownAttention Deficit Hyperactivity Disorder | Disruptive Mood Dysregulation DisorderNorway
-
Peter TonnUniversitätsklinikum Hamburg-EppendorfRecruiting
-
Children's Hospital Medical Center, CincinnatiNational Institute of Mental Health (NIMH)CompletedAttention Deficit Hyperactivity Disorder | Adherence, MedicationUnited States
-
Haukeland University HospitalActive, not recruiting
-
Children's Hospital Medical Center, CincinnatiCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Karolinska InstitutetDepartment of ADHD, Northern Stockholm PsychiatryCompleted